István Édes

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo et al. · The Lancet Respiratory Medicine · 2017 · 264 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus

Markku S. Nieminen, Johann Altenberger, Tuvia Ben‐Gal et al. · International Journal of Cardiology · 2014 · 66 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Contemporary Management of Severe Symptomatic Aortic Stenosis

M Eugène, Piotr Duchnowski, Bernard Prendergast et al. · Journal of the American College of Cardiology · 2021 · 53 citations · Full text

Medicine, Cardiology, Surgery +14